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Fiberoptic bronchoscopeAbstract Background: Dexmedetomidine has sedative and sympatholytic effects. The use of
dexmedetomidine in flexible fiberoptic bronchoscopy will attenuate hemodynamic response without
respiratory depression. The aim of this study was to evaluate the clinical efficiency and safety of
dexmedetomidine, and to compare it with the combination of propofol-fentanyl as sedation during
flexible fiberoptic bronchoscopy.
Patients and methods: Seventy-two patients scheduled for elective fiberoptic bronchoscopy were
included and divided into two equal groups. In propofol-fentanyl group (group PF) patients
received 0.5–1 mg/kg propofol and 1 lg/kg of fentanyl. Boluses of 20 mg of propofol were given
to give a sedation level of 3–4 according to Ramsay sedation score. In dexmedetomidine group
(group D), dexmedetomidine 1 lg/kg over 10 min was given as a loading dose, followed by a main-
tenance infusion of 0.2–0.7 lg/kg/h to keep the same level of sedation. Heart rate, blood pressure
and oxygen saturation were recorded.
Results: Heart rate and mean arterial blood pressure values were significantly lower in group D
compared to group PF all over the procedure. Group D had higher oxygen saturation values than
group PF. Incidence of desaturation was more frequent in PF group (16.66%) compared to 5.55%
in group D. There was no significant difference in patient satisfaction between the two groups.
Conclusion: Dexmedetomidine and propofol-fentanyl are effective sedatives for patients undergo-
ing flexible fiberoptic bronchoscopy. The sympatholytic and respiratory stability effects of
dexmedetomidine make it an attractive and safe alternative for sedation during FOB.
 2016 Publishing services by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Flexible fiberoptic bronchoscopy (FOB) is usually performed
by pulmonologist, and is the gold standard for visualizing
the airway allowing many diagnostic and therapeutic interven-
tions. The widespread use of the flexible bronchoscope makes
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adjunct to topical anesthesia [1]. Many sedative protocols have
been investigated. Midazolam in addition to an opioid is the
most common combination used to improve patient tolerance
and satisfaction [2]. Using intermittent propofol boluses pro-
vides good tolerance and fast recovery for patients undergoing
FOB [3]. The addition of opioids may provide antitussive
effect, and also they modify the pharmacokinetics of propofol,
which decreases the required propofol dose [4,5]. Opioids are
frequently used in FOB in combination with benzodiazepines
as they provide analgesic, anti-tussive and sedative effects.
Alfentanil is ideal for FOB as it has fast onset and short
duration [6,7]. Fentanyl is 100 times as potent as morphine
with rapid onset and short elimination half-life which makes
it suitable for use in bronchoscope [1]. Dexmedetomidine
(PrecedexTM, Dexmedetomidine HCl Injection, Hospira
Healthcare Corporation) is a highly selective a2-adrenergic
agonist; it has sedative and analgesic properties. Dexmedeto-
midine does not cause respiratory depression in comparison
with other sedatives [8]. It has sympatholytic effect that causes
reduction in heart rate and blood pressure, which correlates
with reductions in plasma levels of catecholamines [9,10].
These effects make dexmedetomidine an attractive choice for
sedation during FOB. This prospective randomized trial was
designed to evaluate the clinical efficacy and safety of
dexmedetomidine, and to compare it with the combination
of propofol-fentanyl for sedation during flexible fiberoptic
bronchoscopy.Table 1 Ramsay sedation scale [11].
1 Patient is anxious or agitated
2 Patient is cooperative, oriented and tranquil
3 Patient responds to commands only
4 Patient exhibits brisk response to light glabellar tap or loud
auditory stimulus
5 Patient exhibits a sluggish response to light glabellar tap or loud
auditory stimulus
6 Patient exhibits no response2. Patients and methods
This prospective randomized study was conducted in Ain-
Shams University hospital in a period of nine months. After
obtaining approval from department ethical committee, 72
adult patients aged 18–70, ASA I to III scheduled for elective
flexible fiberoptic bronchoscopy were studied. FOB was per-
formed for diagnostic purposes, with or without lung biopsy
e.g. in patients with a hilar mass or nodule, lung cancer stag-
ing, hemoptysis and interstitial lung disease.
Written informed consent was obtained from all patients.
Exclusion criteria included patients with oxygenation failure
(baseline oxygen saturation 90% or less), bronchial asthma,
or had chronic obstructive pulmonary disease with forced expi-
ratory volume in 1 s (FEV1) less than 50% of the predicted.
Patients with heart rhythm disturbance, bradycardia (heart
rate less than 60 BPM), hypotension (systolic arterial pressure
<100 mmHg), untreated coagulopathy, acute myocardial
ischemia, chronic or acute intake of any sedative drugs or
other a2 agonists, and intubated patients were also excluded.
None of the patients received any premedication.
All patients received topical airway anesthesia with lido-
caine spray 10% in the oral cavity and injection of lidocaine
2% 8 ml aliquots via the bronchoscope suction port as it was
advanced to suppress cough reflex, and this was performed
by the bronchoscopist. Fiberoptic bronchoscopy was per-
formed transorally in the supine position. During the proce-
dure, supplementary oxygen via a nasal cannula 3 L/min was
given to all patients. Continuous ECG, pulse oximetry and
non-invasive blood pressure every 3 min were recorded.
Patients were monitored during the procedure and until dis-
charge from the post anesthesia care unit.Patients were randomly allocated into two equal groups
using computer-generated random list, and 72 sealed envelopes
were prepared and coded (36 envelopes for each group). In
propofol-fentanyl group (group PF), a loading dose 0.5–
1 mg/kg of propofol and 1 lg/kg of fentanyl were given to give
a sedation level of 3–4 according to Ramsay sedation score
(Table 1) [11]. A bolus of 20 mg of propofol was given to main-
tain the same level of sedation. Propofol boluses administra-
tion was based on clinical response. In the Dexmedetomidine
group (group D), dexmedetomidine was given at a rate of
1 lg/kg over 10 min as a loading dose, followed by a mainte-
nance infusion rate of 0.2–0.7 lg/kg/h to keep the same level
of sedation. In both groups cough, movement or agitation,
were considered indicators of inadequate sedation to adjust
the rate of dexmedetomidine infusion or give bolus dose of
propofol.
Time to start the procedure, defined as the time from giving
the sedative drug to the beginning of bronchoscopy was
recorded. Changes in mean arterial blood pressure, heart rate,
and oxygen saturation were recorded at specific time intervals;
before giving the sedation (baseline), after administration of
the study drug and until the patient achieved a sedation score
of 3 (T1), at the beginning of the procedure, during advancing
the bronchoscope through the vocal cords (T2), and every
3 min for three successive times. Incidence of adverse events
was recorded and managed as follows: Oxygen desaturation
(sat < 90%) was managed by increasing oxygen flow to 6 L/
min or jaw support if required. Persistent hypoxia for more
than one min necessitated withdrawal of bronchoscope and
mask ventilation. If desaturation is not corrected by mask ven-
tilation for more than two minutes endotracheal intubation
should be done. Hypotension (systolic BP < 90 mmHg) was
managed by IV crystalloids resuscitation. Bradycardia (heart
rate < 50 bpm) was treated with IV atropine 0.01 mg/kg.
Any other adverse outcomes were reported if happened.
Drug administration was terminated and disconnected
from the patient when the bronchoscopist indicated that the
procedure was finished. Patients were transferred to the
postanesthesia care unit and stayed until fully awake. Once
the patients were oriented they were questioned how comfort-
able/uncomfortable they felt during the procedure, they were
asked to rate their level of satisfaction during FOB on a three
point scale (satisfied, neutral, or unsatisfied), and this was per-
formed by independent nurse anesthetists blinded to the type
of sedation regimen.
2.1. Sample size
In a study carried out by Ryu et al. [12] the incidence of oxygen
Desaturation in the PR group (propofol–remifentanil) group
Table 2 Comparison between the two intervention groups (Dexmedetomidine) and (Propofol-fentanyl) as regard Age, Sex, Weight,
Time to start Procedure, Duration of FOB.
Patient Characteristics Group D (n= 36) Group PF (n= 36) t-Value P-value
Age (years) 50.3 ± 14.9 47.9 ± 15.3 0.502 0.619
Sex No % No % CHI2 value*
Male 23 63.9 25 69.4 0.250 0.617
Female 13 36.1 11 30.6
Weight (kg) 77.9 ± 14.2 80.3 ± 14.0 0.536 0.595
Time to start procedure (min) 10.5 ± 2.1 2.7 ± 0.73 15.431 0.000*
Duration of FOB (min) 21.8 ± 3.9 21.5 ± 3.6 0.251 0.803
Values are presented as Mean ± SD or number (%).
* Chi square test.
Table 3 Comparison between the two intervention groups (Dexmedetomidine) and (Propofol-fentanyl) as regard HR.
HR (BPM) Group D (n= 36) Group PF (n= 36) t-Value P-value
Baseline 86.0 ± 13.9 86.5 ± 14.1 0.101 0.920
After Sedation (T1) 66.3 ± 10.5 77.5 ± 12.9 3.002 0.0055*
At the start of FOB (T2) 85.6 ± 8.1 96.8 ± 11.9 3.464 0.001*
3 Min 79.5 ± 7.4 93.5 ± 8.9 5.365 0.000*
6 Min 78.3 ± 7.7 89.3 ± 7.6 4.518 0.000*
9 Min 75.5 ± 8.4 89.3 ± 8.2 5.218 0.000*
Values are presented as Mean ± SD.
BPM: Beat per minute.
After sedation (T1): the time the patients achieved a sedation score of 3.
At the start of FOB (T2): during advancing the bronchoscope through the vocal cords.
* Statistically significant at P< 0.05.
Table 4 Comparison between the two intervention groups (Dexmedetomidine) and (Propofol + fentanyl) as regards MAP.
MAP (mmHg) Group D (n= 36) Group PF (n= 36) t-value P-value
Baseline 90.9 ± 8.2 88.9 ± 8.5 0.772 0.445
After sedation (T1) 86.4 ± 6.8 80.4 ± 8.9 2.384 0.022*
At the start of FOB (T2) 86.4 ± 6.8 95.1 ± 8.1 3.624 0.001*
3 min 80.7 ± 7.0 89.2 ± 7.8 3.606 0.001*
6 min 78.0 ± 7.7 87.3 ± 7.4 3.865 0.000*
9 min 77.3 ± 7.2 89.3 ± 8.0 4.973 0.000*
Values are presented as Mean ± SD.
HR: heart rate.
MAP: mean arterial pressure.
After sedation (T1): the time the patients achieved a sedation score of 3.
At the start of FOB (T2): during advancing the bronchoscope through the vocal cords.
* Statistically significant at P< 0.05.
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PD group (propofol–dexmedetomidine) group was 3%
(a= 0.05, power = 0.8). Sample Size Calculation was done
using STATCALC Epi-Info version 7 showed that 32 subjects
per group would be sufficient to detect a difference between the
two groups. Assuming a 10% dropout rate, the final sample
size was set at 36 patients per group.
2.2. Statistical methods
Analysis was performed using SPSS version 17.0 for Windows
(SPSS, Chicago, IL, USA). Student’s t-test (two-sided) wasused to compare group continuous variables. The Chi square
test was used to analyze categorical variables. Data are pre-
sented as mean (SD) or as count (%). Two-sided P-values of
0.05 were considered significant.
3. Results
Seventy-two patients were included in this study and were
divided into 2 groups, 36 patients each. No case had to be ter-
minated prematurely because of patient intolerance or over
sedation. There was no significant difference between the 2
groups with respect to age, weight, gender and duration of
Table 5 Comparison between the two intervention groups (Dexmedetomidine) and (Propofol-fentanyl) as regards O2 saturation.
O2 Saturation (%) Group D (n= 36) Group PF (n= 36) t-Value P-value
Baseline 96.7 ± 1.8 97.1 ± 1.8 0.756 0.454
After sedation (T1) 96.2 ± 1.8 96.2 ± 1.8 0.000 1.000
At the start of FOB (T2) 93.4 ± 2.8 90.9 ± 3.9 2.286 0.028*
3 Min 95.6 ± 1.8 93.6 ± 2.6 2.845 0.007*
6 min 95.6 ± 1.7 95.2 ± 1.6 0.643 0.524
9 min 96.0 ± 1.7 95.2 ± 1.6 1.551 0.129
Values are presented as Mean ± SD.
After sedation (T1): the time the patients achieved a sedation score of 3.
At the start of FOB (T2): during advancing the bronchoscope through the vocal cords.
* Statistically significant at P< 0.05.
Table 6 Comparison between the two intervention groups (Dexmedetomidine) and (Propofol + fentanyl) as regard incidence of
complications and patient satisfaction.
Type of complications Group P-value
Group D (n= 36) Group PF (n= 36)
Bradycardia HR< 55 bpm No 8 2 0.084
% 22.22% 5.55%
Hypotension MBP< 55 mmHg No 6 3 0.478
% 16.66% 8.33%
O2 desaturation (apnea or airway obstruction that needs mask ventilation) No 2 6 0.260
% 5.55% 16.66%
Patient satisfaction 0.883
Satisfied 30 (83%) 29(80.5%)
Neutral 5 (14%) 5 (14%)
Unsatisfied 1(3%) 2(5.5%)
Fisher Exact Test was used as expected count less than 5.
bpm: beat per minute.
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group PF compared with group D (Table 2).
Tables 3 and 4 demonstrate that baseline hemodynamics
(HR and MAP) were comparable between the 2 groups. After
sedation (T1) group D showed significant decrease in HR val-
ues compared to group PF (P-value 0.0055), and at the start of
the procedure (T2) there was significant increase in HR and
MAP in group PF compared to group D (P-value 0.001 at
start of FOB). During the procedure heart rate and MAP val-
ues were significantly lower in group D compared to group PF.
After sedation there was no statistically significant
difference in SpO2 between both groups. At the start of
FOB Group D had significantly higher SpO2 than group PF
(P-value 0.028). Comparing SpO2 afterward group D had
higher values than group PF during the procedure, however
the changes were not statistically significant except after
3 min where P-value was 0.007 (Table 5).
Incidence of complications is summarized in Table 6, and
there was no statistically significant difference between the
two groups. Bradycardia HR< 55 Beat/min was a common
adverse event in group D (22.22% versus 5.55% in PF group);
however, it was not statistically significant (P-value 0.084).
More patients in group D had MAP of less than 55 mmHg
16.66% versus 8.33% in group PF, but the difference is statis-
tically insignificant. Three cases, two in group D and one in
group PF, had an episode of both hypotension and bradycar-dia. All patients in both groups responded well to medical
treatment, and there was no hemodynamic compromise as a
result of changes in HR or BP.
Apnea or airway obstruction was the causes of O2 desatu-
ration <90%, that was not responding to increased O2 flow to
6 L/min or jaw support and needed mask ventilation. The
numbers shown in Table 6 represent the number of patients
that had desaturation <90% (based on SpO2). Desaturation
occurred more frequent in PF group (16.66%) in comparison
with 5.55% in group D, however the difference is statistically
insignificant. No patient in both groups had persistence desat-
uration which needed ETT.
There was no significant difference in patient satisfaction
between the two groups (Table 6), and more than 80% of
patients in both groups were satisfied by the procedure.4. Discussion
Dexmedetomidine is a lipophilic a-2 agonist which sedates
through its action on the locus coeruleus, the predominant
noradrenergic nucleus in the brain [13].
It was theorized that the use of dexmedetomidine sedation
in FOB would attenuate hemodynamic responses without res-
piratory depression, so this prospective randomized study was
conducted to compare dexmedetomidine with intermittent
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bronchoscopy in terms of respiratory depression, and
hemodynamic stability. Oxygen desaturation is a common
complication during FOB, with or without O2 supplementa-
tion. It may be caused by many factors, including hypoventila-
tion secondary to using sedation, application of local
anesthetic, or partial airway obstruction caused by the bron-
choscope itself [14,15].
Propofol has been described as an ideal agent for flexible
bronchoscopy sedation due to its fast onset and rapid recovery
profile [16]. However controversy continues because of individ-
ualized patient response to propofol and easy shift to deeper
levels of sedation with an associated risk of cardiopulmonary
depression [17].
The addition of an opioid to propofol can be useful because
of the antitussive effect of opioids and the enhancement of
sedation quality. Many studies performed using combination
of propofol and opioids had been accepted for patient sedation
during bronchoscopy [18,6,19]. On the other hand, a prospec-
tive study was performed by Yoon et al. [20] to compare
propofol-only sedation with propofol–alfentanil combination
sedation in patients undergoing FOB, and they concluded that
the combination of propofol and alfentanil resulted in a
greater respiratory depression than propofol alone; further-
more, the addition of an opioid did not improve the quality
of sedation. Stolz et al. [16] reported that, if supplemental oxy-
gen is routinely provided during bronchoscopy propofol does
not cause a greater fall in arterial oxygen saturation than does
the combination of midazolam and hydrocodone.
Lin and colleagues [21] used propofol sedation in FOB and
they noted that reducing or even managing without opioids
may reduce the rate of hypoxemia.
In the present study patients in dexmedetomidine group
had higher oxygen saturation values, throughout the proce-
dure, compared to propofol group, though there was no signif-
icant difference, except at the start and 3 min from the start of
FOB. Oxygen desaturation that required intervention occurred
more frequently in patients of propofol group, with no
significant difference, patients responded to jaw thrust and
mask ventilation for one minute or less. No patient had pro-
longed desaturation that needed ETT. The addition of fentanyl
did not cause significant effect on ventilation. Prophylactic
oxygen supplement by nasal cannula was important and may
had led to reduce the hypoxic episodes. Also monitoring the
patients with pulse oximetry is an essential guideline during
bronchoscopy [22].
The outcome of this study that dexmedetomidine caused
less incidence of desaturation is supported by many previous
studies, which were tested sedation with dexmedetomidine in
FOB. Ryu and colleagues [12] compared it with remifentanil
and reported that dexmedetomidine was associated with lower
incidences of oxygen desaturation than remifentanil during
flexible bronchoscopy.
Another pilot study was conducted by Abouzgheib et al.
[23]. They tested the efficiency and safety of dexmedetomidine
sedation for bronchoscopy in patients with moderate to severe
COPD, they enrolled patients with forced expiratory volume in
one second less than 50% of the predicted, and they found that
no patient demonstrated marked hypotension or hypertension,
bradycardia, apnea, or desaturation during the procedure.
Liao et al. [24] showed that dexmedetomidine offered better
oxygen saturation and steadier hemodynamics than midazo-lam when used for conscious sedation for postoperative
patients undergoing bronchoscopy.
Another favorable characteristic Dexmedetomidine has is
its sympatholytic effects that further differentiate it from ben-
zodiazepines, narcotics, and propofol. Dexmedetomidine
blunts the deleterious cardiovascular responses (hypertension,
tachycardia) to noxious stimuli, [25] and the hemodynamic
response to awake fiberoptic intubation [26].
This study showed that in patients sedated with dexmedeto-
midine the hemodynamic response to insertion of FOB (HR
and BP values) throughout the procedure was significantly
lower than patients in propofol group. However no patient
in propofol-fentanyl group had severe tachycardia and/or
hypertension which required treatment. The significant differ-
ence in hemodynamics between both groups mostly because
propofol, in the current study, was compared with dexmedeto-
midine which has a great sympatholytic effect, in contrast to
Oztu¨rk et al’s study [27], in which propofol caused lower
hemodynamic side effects when used as sedative for FOB when
compared with midazolam.
Patients in both groups tolerated well the procedure and
had high satisfaction scores.
There are two limitations of this study, first that the study
was not blind, which was because the way of insertion and the
color of both drugs were different. Second, patients with FEV1
less than 50% of predicted were excluded, which may have pre-
vented serious O2 desaturation to occur in both groups.
In conclusion, dexmedetomidine and propofol are effective
for sedation in patients undergoing flexible fiberoptic bron-
choscopy with high patient satisfaction. The sympatholytic
and respiratory stability effects of dexmedetomidine make it
an attractive and safe alternative for sedation during FOB.
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